Verastem, Inc. (VSTM) Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Verastem, Inc. on October 19, 2025. The filing discloses updated clinical data for the Company's lead oncology program, VS-7375 (GFH375 in China), a KRAS G12D inhibitor. The data pertains to a Phase 1/2 monotherapy study conducted in China by partner GenFleet Therapeutics (Shanghai), Inc., focusing on patients with advanced pancreatic ductal adenocarcinoma (PDAC).
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial updates and regulatory disclosures.
Material Changes and Clinical Data
The report details significant efficacy and safety data from the VS-7375 study as of the September 27, 2025 data cutoff:
- Study Population: 66 patients with advanced KRAS G12D mutant PDAC; 59 were heavily pre-treated (at least two prior lines of therapy).
- Efficacy Results (59 evaluable patients):
- Overall Response Rate (ORR): 40.7% (24/59).
- Disease Control Rate (DCR): 96.7% (57/59).
- Target Lesion Reduction: 91.5% of patients.
- Overall Survival (OS) at 4 months: 92.2%.
- Median OS: Not reached (median follow-up 5.65 months).
- Median Progression-Free Survival (PFS): 5.52 months.
- 4-month PFS rate: 78.2%.
- Treatment Duration: 31 patients (47%) remained on treatment at evaluation, with the longest duration exceeding one year (367 days).
- Safety Profile: Consistent with prior reports. Most frequent treatment-related adverse events (TRAEs) included diarrhea, neutrophil count decreased, vomiting, and nausea. Grade 3 TRAEs occurred in 30.3% of patients; one Grade 4 TRAE (neutropenia) was reported. No TRAE-related deaths occurred.
Guidance, Outlook, and Management Commentary
Management highlighted the presentation of this data as a late-breaking abstract at the European Society for Medical Oncology 2025. The Company noted that the U.S. Investigational New Drug (IND) application for VS-7375 was cleared in April 2025, with a Phase 1/2a clinical trial initiated in June 2025. The filing does not contain specific financial guidance or forward-looking projections regarding revenue or cash burn.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed statistical tables and subgroup analyses.
- Confirm the status and enrollment progress of the U.S. Phase 1/2a trial initiated in June 2025.
- Review the Company's most recent 10-Q or 10-K for current cash position and runway, as this 8-K contains no financial data.
- Monitor upcoming regulatory milestones for VS-7375 in both the U.S. and China.
- Assess the commercial partnership terms with GenFleet Therapeutics regarding milestone payments or royalties triggered by these data results.